I-Factor is just one of two FDA approved Class III drug-device bone grafts with a spinal indication, according to a July 19 press release.
By expanding its facility, Cerapedics is adding over 50 percent more space for manufacturing, research and development. It has hired more than 100 employees in the state in the last five years and plans to add another 60 by the end of 2024.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
